company background image
SZLS

StageZero Life Sciences TSX:SZLS Stock Report

Last Price

CA$0.07

Market Cap

CA$7.4m

7D

7.7%

1Y

-70.2%

Updated

26 Jan, 2023

Data

Company Financials

StageZero Life Sciences Ltd.

TSX:SZLS Stock Report

Mkt Cap: CA$7.4m

SZLS Stock Overview

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada.

SZLS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

My Notes

New

Notes are coming soon

StageZero Life Sciences Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for StageZero Life Sciences
Historical stock prices
Current Share PriceCA$0.07
52 Week HighCA$0.28
52 Week LowCA$0.055
Beta0.96
1 Month Change16.67%
3 Month Change-12.50%
1 Year Change-70.21%
3 Year Change-80.56%
5 Year Change-94.17%
Change since IPO-99.71%

Recent News & Updates

Recent updates

Imagine Holding StageZero Life Sciences (TSE:SZLS) Shares While The Price Zoomed 465% Higher

Jan 25
Imagine Holding StageZero Life Sciences (TSE:SZLS) Shares While The Price Zoomed 465% Higher

Shareholder Returns

SZLSCA BiotechsCA Market
7D7.7%3.8%0.7%
1Y-70.2%-0.2%-0.4%

Return vs Industry: SZLS underperformed the Canadian Biotechs industry which returned -0.2% over the past year.

Return vs Market: SZLS underperformed the Canadian Market which returned -0.4% over the past year.

Price Volatility

Is SZLS's price volatile compared to industry and market?
SZLS volatility
SZLS Average Weekly Movement11.1%
Biotechs Industry Average Movement10.4%
Market Average Movement9.9%
10% most volatile stocks in CA Market19.5%
10% least volatile stocks in CA Market3.9%

Stable Share Price: SZLS is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: SZLS's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199880James Howard-Tripphttps://www.stagezerolifesciences.com

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company’s lead product is Aristotle, a multi-cancer panel test for simultaneously screening for various cancers from a single sample of blood with high sensitivity and specificity for each cancer.

StageZero Life Sciences Ltd. Fundamentals Summary

How do StageZero Life Sciences's earnings and revenue compare to its market cap?
SZLS fundamental statistics
Market CapCA$7.38m
Earnings (TTM)-CA$5.64m
Revenue (TTM)CA$6.19m

1.2x

P/S Ratio

-1.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SZLS income statement (TTM)
RevenueUS$4.62m
Cost of RevenueUS$4.74m
Gross Profit-US$122.57k
Other ExpensesUS$4.09m
Earnings-US$4.21m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.04
Gross Margin-2.65%
Net Profit Margin-91.17%
Debt/Equity Ratio104.6%

How did SZLS perform over the long term?

See historical performance and comparison